ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "prognostic factors"

  • Abstract Number: 1455 • ACR Convergence 2022

    Immune Thrombocytopenic Purpura and Subsequent Development of Systemic Lupus Erythematosus

    Gelsomina Alle1, Marina Scolnik1, VALERIA SCAGLIONI1, John Fredy Jaramillo Gallego1, Mayra Alejandra Tobar Jaramillo1, Rodolfo Alvarado1, Enrique R Soriano2 and Javier Eduardo Rosa1, 1Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 2Rheumatology Unit and University Institute, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

    Background/Purpose: The aim of this study is to assess the incidence of Systemic Lupus Erythematosus (SLE) in a cohort of patients with Immune Thrombocytopenic Purpura…
  • Abstract Number: 0676 • ACR Convergence 2022

    Presentation and Outcomes in Patients with Adrenal Hemorrhage Associated with Antiphospholipid Syndrome: A Cohort Study and Systematic Review of Literature

    Jose A Meade-Aguilar1, Gabriel Figueroa Parra1, Jeffrey X. Yang1, Hannah Langenfeld2, Prerna Dogra1, Irina Bancos3, Hassan Murad3, Cynthia Crowson4 and Ali Duarte-Garcia1, 1Mayo Clinic, Rochester, MN, 2Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, 3Mayo Clinic, Rochester, 4Mayo Clinic, Eyota, MN

    Background/Purpose: To describe the clinical characteristics, therapies, and outcomes of patients with antiphospholipid syndrome (APS) and adrenal hemorrhage (AH).Methods: We performed a multicenter retrospective cohort…
  • Abstract Number: 1524 • ACR Convergence 2022

    Risk Factors for Lung Function Decline in Systemic Sclerosis Interstitial Lung Disease in a Large Single-Center Cohort

    Ahmad Ramahi1, Alain Lescoat2, David Roofeh1, Vivek Nagaraja1, Rajaie Namas3, Suiyuan Huang1, John Varga1, David O’Dwyer1, Bonnie Wang1, Kevin Flaherty1, Ella Kazerooni1 and Dinesh Khanna4, 1University of Michigan, Ann Arbor, MI, 2CHU Rennes - University Rennes 1, Rennes, France, 3Medical Subspecialties Institute, Division of Rheumatology at Cleveland Clinic, Abu Dhabi, United Arab Emirates, 4Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI

    Background/Purpose: Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is the leading cause of scleroderma-related mortality. This work identifies factors associated with SSc-ILD decline on pulmonary function…
  • Abstract Number: 0083 • ACR Convergence 2021

    Cardiac Valve Surgery Outcomes in the Antiphospholipid Syndrome

    Tali Eviatar1, Stanley Niznik2, Nancy Agmon-Levin2 and Daphna Paran3, 1Tel Aviv Sourasky Medical Center, Givataim, Israel, 2Sheba Medical Center, Ramat Gan, Israel, 3Tel Aviv Sourasky Medical Center-Ichilov Hospital, Even Yehuda, Israel

    Background/Purpose: Cardiac valve involvement in the APS is prevalent, necessitating valve surgery in about 5% of the patients. Data regarding valve surgery outcomes in APS…
  • Abstract Number: 1834 • ACR Convergence 2021

    To What Extent Do Clinical Features of PsA Predict Achievement of Minimal Disease Activity at Week 24: A Post Hoc Analysis of the Phase III Clinical Trial Program of Guselkumab in a Bio-naïve Patient Population

    Marijn Vis1, Pascal Richette2, Ramirez Julio3, Marlies Neuhold4, Robert Wapenaar5, Elke Theander6, Wim Noel7, May Shawi8, Alexa Kollmeier9 and William Tillett10, 1Erasmus MC, Badhoevedorp, Netherlands, 2Lariboisiere Hospital, Paris, France, 3Hospital Universitari Clinic, Barcelona, Spain, 4Janssen-Cilag, Zug, Switzerland, 5Janssen-Cilag BV, Breda, Netherlands, 6Janssen Cilag, Lund, Sweden, 7Janssen Pharmaceutica, Vilvoorde, Belgium, 8Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, 9Janssen Research & Development, LLC, La Jolla, CA, 10Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom

    Background/Purpose: Guselkumab (GUS), a human monoclonal antibody targeting the interleukin-23p19-subunit, has demonstrated efficacy across joint and skin endpoints at Week 24 (W24) in the Phase…
  • Abstract Number: 0254 • ACR Convergence 2021

    Patient and Disease-Level Factors Associated with Sustained Cessation of Medication for Disease Remission in Systemic Juvenile Idiopathic Arthritis

    Elaine Flanagan1, Rosemary Peterson2, Susan Shenoi3, Helena Chang4, Kelly Wang4, Rebecca Trachtman4 and Karen Onel5, 1Emory/CHOA, Atlanta, GA, 2Dell Children's Medical Center, Austin, TX, 3Seattle Children's Hospital, Seattle, WA, 4Icahn School of Medicine at Mount Sinai, New York, NY, 5Hospital for Special Surgery, New York, NY

    Background/Purpose: The emergence of IL-1 and IL-6 inhibitors (biologics) for the treatment of systemic juvenile idiopathic arthritis (SJIA) has dramatically improved patient outcomes. With higher…
  • Abstract Number: 1848 • ACR Convergence 2021

    Untangling the Gut: A Phenome-Wide Association Study of Drugs and Diseases with Gastrointestinal Dysfunction in Systemic Sclerosis

    Rory Maclean1, Fiza Ahmed2, Voon Ong3, Charles Murray4 and Christopher Denton5, 1Royal Free Hospital & University College London, London, United Kingdom, 2Royal Free Hospital, Ilford, United Kingdom, 3University College London Medical School Royal Free Campus, London, United Kingdom, 4Royal Free Hospital, London, United Kingdom, 5University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom

    Background/Purpose: Gastrointestinal dysfunction (SSc-GI) is a significant burden to patients with systemic sclerosis (SSc), particularly in those with longstanding disease. The management of SSc-GI is…
  • Abstract Number: 0344 • ACR Convergence 2021

    Anti-gAChR Antibody as a Novel Biomarker for Lupus Enteritis in Systemic Lupus Erythematosus

    Kuniyuki Aso1, Michihito Kono1, Keita Ninagawa1, Nobuya Abe1, Yuichiro Fujieda1, Masaru Kato1, Olga Amengual1, Kenji Oku1 and Tatsuya Atsumi2, 1Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, 2Hokkaido University, Sapporo, Japan

    Background/Purpose: Anti-ganglionic nicotinic acetylcholine receptor (gAChR) antibody (Ab) is associated with widespread autonomic dysfunction in autoimmune autonomic ganglionopathy. Although it is also detected in several…
  • Abstract Number: 0388 • ACR Convergence 2021

    Prediction Tool for Damage Accrual Trajectory in Incident Systemic Sclerosis

    Ariane Barbacki1, Ada Man2, Mianbo Wang3, Dylan Johnson4, Yuqing Zhang5, Mandana Nikpour6 and Murray Baron7, 1McGill University, Montral, Montréal, QC, Canada, 2University of Manitoba, Winnipeg, MB, Canada, 3Lady Davis institute for Medical Research, Montréal, QC, Canada, 4University of Alberta, Edmonton, AB, Canada, 5Massachusetts General Hospital, Quincy, MA, 6University of Melbourne at St Vincent's Hospital, Melbourne, Australia, 7Jewish General Hospital, Montréal, QC, Canada

    Background/Purpose: Systemic sclerosis (SSc) is a systemic autoimmune disease associated with the accrual of organ damage over time, which can be measured using the Scleroderma…
  • Abstract Number: 0532 • ACR Convergence 2021

    Development of a Predictive Tool for the Rapid Progressive Knee Osteoarthritis Phenotype: Data from the Osteoarthritis Initiative

    Alejandro Durán-Sotuela1, Mercedes Fernández-Moreno1, Maria Vázquez-Mosquera1, Paula Ramos-Louro1, Andrea Dalmao-Fernández1, Sara Relaño1, Victoria Suárez-Ulloa2, Vanesa Balboa-Barreiro3, Natividad Oreiro1, Jorge Vázquez-García1, Francisco Blanco-García4 and Ignacio Rego-Pérez1, 1Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain, 2Plataforma de Bioinformática. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006, A Coruña, Spain, 3Unidad de apoyo a la Investigación. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain, 4Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006, A Coruña, España.Universidade da Coruña (UDC), Grupo de Investigación de Reumatología y Salud (GIR-S). Departamento de Fisioterapia, Medicina y Ciencias Biomédicas, Facultad de Fisioterapia, Campus de Oza, 15008, A Coruña, España., A Coruña, Spain

    Background/Purpose: There is a pressing need of identifying patients suffering the rapid progressive phenotype of Osteoarthritis (RPOA) to implement prevention strategies and to include them…
  • Abstract Number: 0702 • ACR Convergence 2021

    Performance of Commercial Autoantibody Testing in Comparison to Recognized Gold Standards in Myositis Autoantibody Testing

    Sarvar Nazir1, Lisa Rider2, Ira Targoff3, Stanley Naides4, Andrew Mammen5, Steven Greenberg6 and Adam Schiffenbauer5, 1NIEHS, NIH, Bethesda, MD, 2NIEHS, NIH, Garrett Park, MD, 3Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Self, Dana Point, CA, 5National Institutes of Health, Bethesda, MD, 6Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: The idiopathic inflammatory myopathies (IIM) are a heterogenous group of autoimmune conditions. The presence of myositis-specific autoantibodies (MSAs) and myositis-associated autoantibodies (MAAs) in patients…
  • Abstract Number: 0707 • ACR Convergence 2021

    Association of Pneumomediastinum with Poor Prognosis in Patients with Myositis-Associated Interstitial Lung Disease

    Kazuki Hirano1, Azusa Kojima1, Akira Ishii1, Mai Sugiyama1, Yuto Izumi1, Noriko Sasaki2, Yuji Hosono1, Chiho Yamada1 and Shinji Sato3, 1Tokai University School of Medicine, Isehara, Japan, 2tokai university, sagamihara-city, Japan, 3Tokai University, Isehara, Japan

    Background/Purpose: Pneumomediastinum is an important complication in patients with myositis-associated interstitial lung disease (ILD). Patients with myositis and ILD who had pneumomediastinum during the disease…
  • Abstract Number: 0965 • ACR Convergence 2021

    Anti-TNF Usage in Patients with HIV Infection 2003-2021: Long Term Safety and Followup

    Benjamin Naovarat1, Francis Williams2, Gloria Salazar3 and John Reveille4, 1University of Texas McGovern Medical School, Houston, TX, 2Specialists for Health/Wellmed, Shavano Park, TX, 3University of Texas Medical School at Houston/McGovern Medical School, Houston, TX, 4Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX

    Background/Purpose: There are concerns about using immunosuppressive agents for treatment of rheumatic diseases in patients with HIV infection due to concerns of opportunistic infection. We…
  • Abstract Number: 1228 • ACR Convergence 2021

    Predicting RA Remission with Subcutaneous Abatacept Treatment in the Real-world Setting

    Rieke Alten1, Christiane Rauch2, Bettina Bannert3, Sara Marsal4, Maya Buch5, Roberto Caporali6, Melanie Chartier7, Sean Connolly8, Hedley Griffiths9, Xavier Mariette10, Michael Nurmohamed11, Yusuf Patel12, Peter Peichl13, Raimon Sanmarti14, Yedid Elbez15 and Karissa Lozenski8, 1Schlosspark-Klinik University, Berlin, Germany, 2Bristol Myers Squibb, Munich, Germany, 3Universitätsspital Basel, Basel, Switzerland, 4Hospital Universitari Vall d’Hebron, Barcelona, Spain, 5University of Leeds, Leeds, United Kingdom, 6Policlinico S. Matteo University, Pavia, Italy, 7Bristol Myers Squibb, Rueil-Malmaison, France, 8Bristol Myers Squibb, Princeton, NJ, 9Barwon Rheumatology Service, Geelong, Australia, 10Université Paris-Saclay, AP-HP, Hospital Bicêtre, Paris, France, 11ARC Amsterdam University Hospitals – VU University Medical & Reade, Amsterdam, Netherlands, 12Hull Royal Infirmary, Hull, United Kingdom, 13Evangelical Hospital, Vienna, Austria, 14Hospital Clínic de Barcelona, Barcelona, Spain, 15Deepscover, Puteaux, France

    Background/Purpose: A treat-to-target approach for RA management is recommended, with the aim of achieving remission.1,2 The Abatacept SubCutaneOus in Routine clinical practicE (ASCORE; NCT02090556) study…
  • Abstract Number: 1356 • ACR Convergence 2021

    Effects of TNF-α versus Secukinumab on Active Ultrasound Confirmed Enthesitis in Psoriatic Arthritis

    Ashley Elliott1, Gary Wright2, Adrian Pendleton2 and Madeleine Rooney1, 1Centre for Experimental Medicine , School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, UK, Belfast, Northern Ireland, United Kingdom, 2Belfast Health and Social Care Trust, Belfast, Northern Ireland, United Kingdom

    Background/Purpose: Enthesitis is an important aspect of disease in PsA and its clinical assessment has problems in terms of sensitivity and overlap with alternative co-morbid…
  • « Previous Page
  • 1
  • …
  • 11
  • 12
  • 13
  • 14
  • 15
  • …
  • 21
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology